Psychedelic Validation, Nasdaq's New Carbon Play, and Decentralized Bitcoin Mining

Psychedelics Are Showing Positive Results in Phase II Clinical Trials

Cybin (NYSE:CYBN) has shared results from their Phase II clinical trial of CYB003, their novel psilocybin analog drug. After just two doses, 79% of patients in the trial struggling from Major Depressive Disorder (MDD) were officially in remission of depressive symptoms.

Carbon Credit Trading is Coming to the Nasdaq

The Nasdaq Exchange has launched a new technology in partnership with Puro Earth which will digitize carbon credits and accelerate institutional access to trading carbon credits globally.

Jack Dorsey is Backing Decentralized Bitcoin Mining

Mummolin, a Wyoming-based Bitcoin mining software company, has raised $6.2 million in a seed round led by Twitter founder Jack Dorsey and notable venture funds. The company is preparing to launch OCEAN, a decentralized mining project that pays miners directly rather than the traditional pooling models that require custodians.

The Sprint

• EnCore Energy (NYSE:EU) is bringing uranium production back to Texas, becoming the first company in the past decade to do so in the state.

• Sky Labs has raised $15 million to advance clinical trials for their wearable ring that can track blood pressure.

• Barclays, one of the largest banks in the UK, is building an institutional trading arm for carbon credits and carbon offsets.

• Else Nutrition (TSXV:BABY) has raised $5 million to advance the research and development of their proprietary plant based baby formula.

Trending Now

• Atari’s Founder is Bringing Video Games to School

• Marathon Digital Wants to Turn Trash Into Bitcoin

• The Next Generation of 3D Metal Printing